Clinical Trials Directory

Trials / Completed

CompletedNCT01342445

Effects of LDX on Functioning of College Students With ADHD

Effects of Vyvanse on the Behavioral, Academic, and Psychosocial Functioning of College Students With ADHD

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
50 (actual)
Sponsor
University of Rhode Island · Academic / Other
Sex
All
Age
18 Years – 28 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to evaluate the effects of lisdexamfetamine dimesylate, a prodrug stimulant, on the behavioral, academic, and psychosocial functioning of college students with attention-deficit/hyperactivity disorder (ADHD). Twenty-five college students with ADHD from two universities (University of Rhode Island and Lehigh University) completed a within-subject, placebo-controlled research trial. Dependent measures tapping behavioral, psychosocial, and academic functioning were completed on a weekly basis across five conditions (baseline, placebo, and 30-mg, 50-mg, and 70-mg lisdexamfetamine).

Detailed description

Objective: Evaluate stimulant medication on symptoms and functioning for college students with ADHD using double-blind, placebo-controlled, crossover design. Method: Participants included 24 college students with ADHD and 26 college students without psychopathology. Lisdexamfetamine dimesylate (LDX) examined for ADHD participants over five weekly phases (no-drug baseline, placebo, 30, 50, \& 70-mg LDX per day). Self-report rating scales of functioning and direct assessment of ADHD symptoms, verbal learning/memory, and adverse side-effects were collected (baseline only for control students).

Conditions

Interventions

TypeNameDescription
DRUGlisdexamfetamine dimesylate30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
DRUGPlacebo

Timeline

Start date
2009-09-01
Primary completion
2010-12-01
Completion
2010-12-01
First posted
2011-04-27
Last updated
2025-04-24
Results posted
2014-04-08

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01342445. Inclusion in this directory is not an endorsement.